Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Lancet Oncol
; 21(5): 655-663, 2020 05.
Article
in En
| MEDLINE
| ID: mdl-32251621
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Carcinoma, Non-Small-Cell Lung
/
Antibodies, Monoclonal, Humanized
/
B7-H1 Antigen
Type of study:
Clinical_trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2020
Type:
Article